Invirsa

Executive Summary

Invirsa is a clinical-stage biotechnology company pioneering a novel approach to DNA damage repair with its lead candidate, INV-102, a first-in-class small molecule designed to enhance the body's natural DNA damage response (DDR). The company is initially targeting ocular and respiratory conditions where DNA damage drives disease pathology, including sulfur mustard gas ocular injury and diabetic dry eye disease. INV-102 aims to stabilize cells during critical damage events, promoting repair and reducing inflammation. Founded in 2016 and headquartered in Cambridge, MA, Invirsa is privately held and has advanced INV-102 into Phase 1/2 clinical trials. The company's lead program in sulfur mustard gas ocular injury addresses a significant unmet need in chemical injury, while its second program in diabetic dry eye targets a large and growing patient population. Invirsa's platform has potential applicability beyond ocular and respiratory indications, given the universal role of DNA damage in various diseases. With early clinical data expected in the near term, the company represents a compelling opportunity in the DDR space. However, as a private early-stage biotech, it faces typical development and financing risks. Upcoming catalysts include clinical data readouts and trial initiations that could validate its platform and drive value.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 interim data for INV-102 in sulfur mustard gas ocular injury60% success
• H1 2027Initiation of Phase 1/2 trial for INV-102 in diabetic dry eye disease70% success